Walgreens Boots Alliance, Inc.

  • Earnings Score
  • Moat Score
  • Safety Score
  • Market Cap $7.39B
  • PE -0
  • Debt $11.09B
  • Cash $3.22B
  • EV $15.26B
  • FCF -$363.00M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$15.45B
EBIT-$14.08B
ROE-129%
ROA-17%
FCF-$363.00M
Equity$12.01B
Growth Stability-2K%
PE-0.48
PEG0.06
PB0.62
P/FCF-20.35
P/S0.05
Price/Cash0.44
Debt/Equity0.92
Debt/FCF-30.54
Net Margins-10%
Gross Margins18%
Op. Margins-10%
Earnings CAGR-5%
Sales Growth YoY6%
Sales Growth QoQ3%
Sales CAGR2%
FCF CAGR-7%
Equity CAGR-4%
Earnings Stability0.03
Earnings Growth YoY1K%
Earnings Growth QoQ-1K%
Earnings CAGR 5Y-9%
Sales CAGR 5Y1%
FCF CAGR 5Y-13%
Equity CAGR 5Y-4%
Earnings CAGR 3Y4%
Sales CAGR 3Y4%
FCF CAGR 3Y-18%
Equity CAGR 3Y-26%
Market Cap$7.39B
Revenue$147.66B
Dividend Yield17%
Payout Ratio-8%
Assets$81.04B
Total Debt$11.09B
Cash$3.22B
Shares Outstanding863.1M
EV15.26B
Earnings Score6%
Moat Score4%
Safety Score37%
Final Score16%
Working Capital-8.62B
Current Ratio0.68
Gross Profit$26.52B
Shares Growth 3y1%
Equity Growth QoQ-21%
Equity Growth YoY-58%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Walgreens Boots Alliance is a leading retail pharmacy chain with about 13,000 stores in the U.S. and internationally. Walgreens' core strategy involves brick-and-mortar retail pharmacy locations in high-traffic areas, with nearly 80% of the U.S. population living within 5 miles of a store. Currently, the company has a leading share of the domestic prescription drug market at about 20%. In 2021, the company sold a majority of its Alliance Healthcare wholesale business to AmerisourceBergen for $6.5 billion, doubling down on its core pharmacy efforts and ventures in strategic growth areas in primary care (VillageMD) and digital offerings. The company also has equity stakes in AmerisourceBergen (29%) and Sinopharm Holding Guoda Drugstore (40%).

SEC Filings

Direct access to Walgreens Boots Alliance, Inc. (WBA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Aug 31
    • 10-Q May 31
    • 10-Q Feb 29
  • 2023
    • 10-Q Nov 30
    • 10-K Aug 31
    • 10-Q May 31
    • 10-Q Feb 28
  • 2022
    • 10-Q Nov 30
    • 10-K Aug 31
    • 10-Q May 31
    • 10-Q Feb 28

Sector Comparison

How does Walgreens Boots Alliance, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Walgreens Boots Alliance, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -5%
Stability 3%
loading chart...

Walgreens Boots Alliance, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Walgreens Boots Alliance, Inc..

= -$2.3B
012345678910TV
fcf-$363M-$337M-$313M-$290M-$269M-$250M-$232M-$215M-$200M-$185M-$172M-$1.7B
DCF-$306M-$258M-$218M-$184M-$155M-$131M-$110M-$93M-$79M-$66M-$664M
Value-$2.3B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years08/201508/201608/201708/201808/201908/202008/202108/202208/202308/2024TTM
Net Margins4%4%3%4%3%0%2%3%-3%-10%-10%
ROA-9%9%11%9%2%5%5%-6%-17%-17%
ROE-14%14%19%16%2%11%14%-12%-129%-129%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years08/201508/201608/201708/201808/201908/202008/202108/202208/202308/2024TTM
Debt over FCF-2.992.252.385.824.712.475.970.99-30.54-30.54
Debt over Equity0.430.640.470.620.940.920.430.430.350.920.92
Growth Stability---100%90%10%80%100%-151%-2K%-2K%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years08/201508/201608/201708/201808/201908/202008/202108/202208/202308/2024CAGR 5Y
Revenue YoY growth-13%1%11%4%2%-5%0%5%6%1%
Earnings YoY growth--1%-2%23%-21%-89%492%62%-187%338%-9%
Equity YoY growth--3%-7%-6%-10%-12%13%23%-4%-58%-4%
FCF YoY growth-48%-10%17%-44%6%2%-48%-93%-357%-13%